Too often, recruiters are more clear on what a position will “do” rather than what it will “achieve”.Outlining tasks and responsibilities takes priority over goals and impact.But to attract top talent, you need to define and explain what success looks…
HOME > COMMENTARY
COMMENTARY
-
Unexpected Demand for ActHIB Causes Shortage of Supply
March 16, 2009
-
COMMENTARY/Aggressive Overseas Investments Affect Business of Top-4 Pharmas
February 23, 2009
-
COMMENTARY/National Consensus Needed to Balance Soaring Costs of New Drugs against Their Benefits
February 16, 2009
-
Majority of People Have Misconceptions about Antibacterials: Pfizer Survey
February 9, 2009
-
Patent Expiration of Blockbusters and New Breakthrough Candidates from Japanese Pharmaceutical Companies
February 9, 2009
-
Paltac/Alfresa Merger Plan Canceled, but Distribution Reform Remains to Be Done
February 2, 2009
-
COMMENTARY/Industry Should Guarantee Development of Innovative Drugs and Use of More Generics
January 19, 2009
-
COMMENTARY/Aiming at Further Growth beyond Global Recession
January 12, 2009
-
COMMENTARY/Rule to Restrict Participation in CDFS Committee Deliberations Needs Continued Validation
January 5, 2009
-
COMMENTARY/Will Economic Incentives for Med. Institutions Be Effective to Promote Use of Generics?
December 22, 2008
-
Commentary/Issue of Online Sales of OTC Drugs at Standstill
December 15, 2008
-
COMMENTARY/Toyota, NEC Start Direct Inspection, Payment of Medical Bills
December 8, 2008
-
COMMENTARY/Will VITAL KSK Become Core of Alliance of Regional Wholesalers?
December 8, 2008
-
SURVEY/DPP-4 Inhibitors May Decrease Consumption of SUs
December 1, 2008
-
COMMENTARY/Thinking about Why Megapharmas Are Closing Research Labs in Japan
November 24, 2008
-
COMMENTARY/Marriage of Nos. 1 and 2 Wholesalers Creates Sensation in Market
November 3, 2008
-
COMMENTARY/Competition Intensifies for Development of DPP-4 Inhibitors
September 22, 2008
-
COMMENTARY/Yamato Searches for a Way to Start Generics Distribution Business
September 22, 2008
-
COMMENTARY/Reform of Ethical Drug Distribution Practices
September 1, 2008
-
COMMENTARY/Gov't to Cut Social Security Spending by \220 Bil by Promoting Use of Generics
August 25, 2008
ページ
Pharmaceutical companies are giving high marks to Japan’s drug pricing reform for FY2024. According to a survey conducted by Jiho, 51% of all respondents expressed a positive opinion of the reform, saying that they were “somewhat satisfied” with it. The…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…